20May

Rapid free light chain test granted registration in Brazil

AbingdonHealth

Seralite® – FLC is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.

This is a key registration for Seralite® – FLC and underpins the regional strategy for Latin America. In conjunction with Seralite® – FLC Serum, Seralite® – FLC LFD Controls and the ADxLR5® Reader System have also been granted registration. Latin America has a population of 606 million people and with a market size of more than US$2.4bn is a key emerging IVD market.

With this registration in Brazil, Seralite® – FLC is now available in 73 countries worldwide. Seralite® – FLC is distributed globally (with the exception of Benelux), by Sebia, the world leader in medical diagnostics for electrophoresis.

Fiona Smith, Sales and Marketing Director, Abingdon Health commented;

“The registration of Seralite® – FLC in Brazil is a milestone registration in South America and supports the global expansion Seralite® – FLC. Our aim is to make free light chain testing available to all clinical laboratories in all areas of the world thus improving patient access to this important diagnostic and monitoring tool for Multiple Myeloma.”

About Abingdon Health

Abingdon is a UK-based developer and manufacturer of lateral flow immunoassay tests and readers.

Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay. Internally Abingdon is focused on developing lateral flow assays in partnership with key opinion leaders that meet significant unmet needs.

Related

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement ...

Read More >

European Reference Laboratory for Glycohemoglobin study reaffirms EKF’s Quo-Test® meets HbA1c performance criteria

Cardiff, UK – 16th February 2017 – EKF Diagnostics, the global in vitro diagnostics company, annou...

Read More >

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >

Psyros Diagnostics Ltd. Awarded £400K Innovate UK Smart Award to accelerate development of their ground-breaking ultra-sensitive IVD technology

30 Sept. 2019, UKCoronary heart disease is one of the leading causes of death within the UK. Every d...

Read More >

EKF Diagnostics publishes ‘Diabetes and HbA1c testing’ guide

Cardiff, UK – 17th July 2017 – EKF Diagnostics, the global in vitro diagnostics company, has publi...

Read More >